These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33324983)

  • 21. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
    Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
    Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
    Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
    Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
    Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
    Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
    Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Perez JR; Agarwal N; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Aug; 15(4):e573-e582. PubMed ID: 28139444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
    Huntoon K; Damante M; Wang J; Olencki T; Elder JB
    Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
    Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
    Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world efficacy and safety of cabozantinib following immune checkpoint inhibitor failure in Japanese patients with advanced renal cell carcinoma.
    Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Hashimoto Y; Kondo T; Takagi T
    Jpn J Clin Oncol; 2023 Oct; 53(10):977-983. PubMed ID: 37519060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.
    Nelson RA; Vogelzang N; Pal SK
    Clin Genitourin Cancer; 2013 Sep; 11(3):303-10. PubMed ID: 23647940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
    Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Ikeda T; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
    Target Oncol; 2023 Mar; 18(2):209-220. PubMed ID: 36941516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases.
    Bowman IA; Bent A; Le T; Christie A; Wardak Z; Arriaga Y; Courtney K; Hammers H; Barnett S; Mickey B; Patel T; Whitworth T; Stojadinovic S; Hannan R; Nedzi L; Timmerman R; Brugarolas J
    Clin Genitourin Cancer; 2019 Apr; 17(2):e263-e272. PubMed ID: 30538068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
    Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
    JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era.
    Lyon TD; Thompson RH; Shah PH; Lohse CM; Boorjian SA; Costello BA; Cheville JC; Leibovich BC
    J Urol; 2020 Feb; 203(2):275-282. PubMed ID: 31393812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.